Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Modus Therapeutics Holding AB's enterprise value is kr55.82 Mil.
Modus Therapeutics Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-18.71 Mil. Therefore, Modus Therapeutics Holding AB's EV-to-EBITDA for today is -2.98.
The historical rank and industry rank for Modus Therapeutics Holding AB's EV-to-EBITDA or its related term are showing as below:
OSTO:MODTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.98 Med: 0 Max: 0
Current: -2.98
OSTO:MODTX's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.825
vs OSTO:MODTX: -2.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Modus Therapeutics Holding AB (OSTO:MODTX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Modus Therapeutics Holding AB's PE Ratio (TTM) for today is calculated as:
Modus Therapeutics Holding AB's share price for today is kr0.422.
Modus Therapeutics Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.217.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MODTX vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Modus Therapeutics Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's EV-to-EBITDA falls into.
Modus Therapeutics Holding AB's current Enterprise Value is kr55.82 Mil.
Modus Therapeutics Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-18.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modus Therapeutics Holding AB (OSTO:MODTX) has a EV-to-EBITDA of -2.98 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Modus Therapeutics Holding AB. According to the industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 402 companies in the Biotechnology industry.
Is Modus Therapeutics Holding AB's EV-to-EBITDA too high?
Modus Therapeutics Holding AB's current EV-to-EBITDA is -2.98. Based on the distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Modus Therapeutics Holding AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 402 companies for EV-to-EBITDA. This places Modus Therapeutics Holding AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.83, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Modus Therapeutics Holding AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modus Therapeutics Holding AB's current EV-to-EBITDA is -2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current EV-to-EBITDA of -2.98. The current EV-to-EBITDA is -2.98. Modus Therapeutics Holding AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current EV-to-EBITDA is -2.98 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
25GF Score
Get the complete analysis for OSTO:MODTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MODTX has been successfully added to your 
